{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:40:13Z","timestamp":1788316813065,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This article synthesizes current preclinical and clinical literature regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in rheumatoid arthritis (RA), highlights mechanistic hypotheses and explores potential clinical roles and limitations of their use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>GLP-1 RAs are established therapies for type 2 diabetes mellitus and obesity, with demonstrated benefits on glycemic control and cardiovascular risk reduction. Emerging evidence suggests that GLP-1 RAs may exert anti-inflammatory and immunomodulatory effects relevant to RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Present evidence is insufficient to recommend GLP-1 RAs as standard RA therapy. Well designed randomized controlled trials are needed to establish their efficacy and optimal role.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001153","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:00:49Z","timestamp":1772704849000},"page":"250-254","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis"],"prefix":"10.1097","volume":"38","author":[{"given":"Ryan","family":"Massay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Malani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"R1-20260528","doi-asserted-by":"crossref","first-page":"103864","DOI":"10.1016\/j.autrev.2025.103864","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists in rheumatology: a review of current evidence and future directions","volume":"24","author":"Bilgin","year":"2025","journal-title":"Autoimmun Rev"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jama.2023.13872","article-title":"Patents and regulatory exclusivities on GLP-1 receptor agonists","volume":"330","author":"Alhiary","year":"2023","journal-title":"JAMA"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2025","journal-title":"JAMA"},{"key":"R4-20260528","doi-asserted-by":"crossref","first-page":"105649","DOI":"10.1016\/j.intimp.2019.05.034","article-title":"Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes","volume":"74","author":"Zheng","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/iub.2031","article-title":"Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"71","author":"Tao","year":"2019","journal-title":"IUBMB Life"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.intimp.2019.105732","article-title":"The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"75","author":"Du","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"103453","DOI":"10.1016\/j.jaut.2025.103453","article-title":"Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: a real-world evidence study","volume":"155","author":"Lee","year":"2025","journal-title":"J Autoimmun"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"847160","DOI":"10.3389\/fimmu.2022.847160","article-title":"Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"R11-20260528","article-title":"Glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and risk of autoimmune rheumatic diseases","author":"Karacabeyli","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"103493","DOI":"10.1016\/j.jaut.2025.103493","article-title":"Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes","volume":"157","author":"Yen","year":"2025","journal-title":"J Autoimmun"},{"key":"R13-20260528","article-title":"Treatment with the glucagon-like peptide-1 analogue liraglutide is associated with amelioration of disease activity in a prospective cohort study of patients with inflammatory arthritis","author":"Sullivan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R14-20260528","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.99.EP24","article-title":"New therapeutic opportunities shared by obesity, type 2 diabetes and rheumatoid arthritis","author":"Gavazova","year":"2024","journal-title":"Endocr Abstr Biosci"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"e70103","DOI":"10.1002\/acr2.70103","article-title":"Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis","volume":"7","author":"Kellner","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"R18-20260528","doi-asserted-by":"crossref","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to antitumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/annrheumdis-2013-205094","article-title":"Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis","volume":"73","author":"Sandberg","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrrheum.2011.107","article-title":"What's new in our understanding of the role of adipokines in rheumatic diseases?","volume":"7","author":"Gomez","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R22-20260528","first-page":"7005","article-title":"Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis","volume":"25","author":"Hu","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1007\/s10067-025-07709-0","article-title":"Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: a global retrospective cohort study","volume":"44","author":"Wang","year":"2025","journal-title":"Clin Rheumatol"},{"key":"R24-20260528","doi-asserted-by":"crossref","DOI":"10.1016\/j.mayocp.2025.09.017","article-title":"GLP1 and GIP receptor agonists: effects on the gastrointestinal tract and management strategies for primary care physicians","author":"Saha","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review","volume":"86","author":"Kunutsor","year":"2026","journal-title":"Drugs"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"12130","DOI":"10.3390\/ijms262412130","article-title":"The influence of glucagon-like peptide-1 receptor agonists and other incretin hormone agonists on body composition","volume":"26","author":"Chrysavgis","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R27-20260528","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70355","article-title":"Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: risks beyond muscle mass reductions","author":"Prokopidis","year":"2026","journal-title":"Br J Pharmacol"},{"key":"R28-20260528","doi-asserted-by":"crossref","first-page":"112924","DOI":"10.1016\/j.diabres.2025.112924","article-title":"GLP-1 receptor agonists and sarcopenia: weight loss at a cost? A brief narrative review","volume":"229","author":"Pantazopoulos","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"R29-20260528","doi-asserted-by":"crossref","first-page":"e0308533","DOI":"10.1371\/journal.pone.0308533","article-title":"Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: a population-based study","volume":"19","author":"Karacabeyli","year":"2024","journal-title":"PLoS One"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:01:02Z","timestamp":1779955262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001153","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}